Cat Number: ABP-0047
Conjugate: Unconjugated
Size: 100 ug
Clone: Poly
Concentration: 1mg/ml
Host: Rb
Isotype: IgG
Reactivity: Hu

WB: 1:1000, IF-IC: 1:200

Molecular Weight: 48 kDa
Purification: Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues around Ser73 of human c-Jun. Antibodies are purified by protein A and peptide affinity chromatography.

c-Jun is a member of the Jun Family con¬taining c-Jun, JunB and JunD, and is a component of the transcription factor AP-1 (activator protein-1). AP-1 is com¬posed of dimers of Fos, Jun and ATF family members and binds to and activates transcription at TRE/AP-1 elements (reviewed in 1). Extracellular signals including growth fac¬tors, chemokines and stress activate AP-1-dependent tran¬scription. The transcriptional activity of c-Jun is regulated by phosphorylation at Ser63 and Ser73 through SAPK/JNK (reviewed in 2). Knock-out studies in mice have shown that c-Jun is essential for embryogenesis (3), and subsequent studies have demonstrated roles for c-Jun in various tissues and developmental processes including axon regeneration (4), liver regeneration (5) and T cell development (6). AP-1 regulated genes exert diverse biological functions including cell proliferation, differentiation, and apoptosis, as well as transformation, invasion and metastasis, depending on cell type and context (7-9). Other target genes regulate survival as well as hypoxia and angiogenesis (8,10). c-Jun has emerged as a promising therapeutic target for cancer, vas¬cular remodeling, acute inflammation, as well as rheumatoid arthritis (11,12). Phospho-c-Jun (Ser73) Antibody detects endogenous levels of c-Jun only when phosphorylated at Ser73.

Form: liquid
Buffer: Supplied in 0.02% sodium azide, 50% glycerol, pH7.3.
Storage: Store at –20°C. Do not aliquot the antibody.

Western blot analysis of extracts of various cell lines, using Phospho-Jun-S73 antibody.


Immunofluorescence analysis using Phospho-c-Jun (Ser73) antibody


(1) Jochum, W. et al. (2001) Oncogene 20, 2401–12. (2) Davis, R.J. (2000) Cell 103, 239–52. (3) Hilberg, F. et al. (1993) Nature 365, 179–81. (4) Raivich, G. et al. (2004) Neuron 43, 57–67. (5) Behrens, A. et al. (2002) EMBO J 21, 1782–90. (6) Riera-Sans, L. and Behrens, A. (2007) J Immunol 178, 5690–700. (7) Leppä, S. and Bohmann, D. (1999) Oncogene 18, 6158–62. (8) Shaulian, E. and Karin, M. (2002) Nat Cell Biol 4, E131–6. (9) Weiss, C. and Bohmann, D. (2004) Cell Cycle 3, 111–3. (10) Karamouzis, M.V. et al. (2007) Mol Cancer Res 5, 109–20. (11) Kim, S. and Iwao, H. (2003) J Pharmacol Sci 91, 177–81. (12) Weiss, C. and Bohmann, D. (2004) Cell Cycle 3, 111–3